BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director V Bryan Lawlis sold 3,750 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $88.84, for a total transaction of $333,150.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
BioMarin Pharmaceutical Inc. (NASDAQ BMRN) traded down $0.08 during trading on Friday, reaching $90.24. 322,415 shares of the company’s stock were exchanged, compared to its average volume of 1,437,100. The firm has a market cap of $15,850.00, a price-to-earnings ratio of -108.72 and a beta of 1.81. BioMarin Pharmaceutical Inc. has a 12 month low of $80.10 and a 12 month high of $100.51. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.81 and a current ratio of 4.91.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The company had revenue of $334.18 million for the quarter, compared to the consensus estimate of $347.38 million. During the same period in the prior year, the firm posted $0.02 EPS. The company’s quarterly revenue was up 19.4% compared to the same quarter last year. analysts predict that BioMarin Pharmaceutical Inc. will post -0.64 EPS for the current year.
BMRN has been the topic of several recent analyst reports. Piper Jaffray Companies initiated coverage on shares of BioMarin Pharmaceutical in a report on Thursday, September 14th. They issued an “overweight” rating and a $113.00 price objective on the stock. Royal Bank of Canada initiated coverage on shares of BioMarin Pharmaceutical in a report on Thursday, September 14th. They issued a “sector perform” rating and a $93.00 price objective on the stock. BMO Capital Markets restated a “buy” rating on shares of BioMarin Pharmaceutical in a report on Friday, September 15th. Jefferies Group restated a “buy” rating and issued a $116.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday, September 26th. Finally, Morgan Stanley restated an “overweight” rating and issued a $117.00 price objective (up from $115.00) on shares of BioMarin Pharmaceutical in a report on Friday, October 6th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. BioMarin Pharmaceutical has a consensus rating of “Buy” and a consensus price target of $112.44.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.